The NAS Perchlorate Review: Questions Remain about the Perchlorate RfD by Ginsberg, Gary & Rice, Deborah
Perchlorate is a widespread contaminant in
drinking water, food, and breast milk
[California Department of Health Services
(CDHS) 2005; Food and Drug Administra-
tion 2004; Kirk et al. 2005]. The U.S.
Environmental Protection Agency (EPA)
developed a draft risk assessment for perchlo-
rate in 2002 (U.S. EPA 2002a, 2003), but
this was recently superceded by an analysis by
the National Academy of Science (NAS
2005). The NAS derived a perchlorate refer-
ence dose (RfD) that is approximately 20-fold
higher (less stringent) than the U.S. EPA
draft RfD from 2002. Without any further
deliberation or public review, the U.S. EPA
has adopted the NAS value and placed it on
its Integrated Risk Information System (IRIS)
website (U.S. EPA 2005), a primary source of
data for state risk assessors.
Given the disparity between the initial U.S.
EPA analysis (U.S. EPA 2002a) and the 2005
NAS report, the perchlorate RfD posted on
IRIS (U.S. EPA 2005) merits careful considera-
tion before health officials embrace this less
stringent value. Our current purpose is to high-
light issues with the primary human studies
used in the NAS perchlorate determination.
However, it is also worth noting that the NAS
discounted the studies in rats, arguing that rats
are more sensitive to the effects of perchlorate
than are humans. We believe that the rat stud-
ies provide important information, particularly
with respect to thyroid suppression, that should
be considered in concert with the human data
as part of a comprehensive risk assessment.
We present the outstanding toxicology
issues, particularly with respect to the human
studies, when considering the public health
implications of perchlorate in drinking water
and the diet.
What Is the NOAEL? 
A key step in deriving any RfD is finding a
dose at which toxic effects can no longer be
demonstrated—the no observable adverse
effect level (NOAEL). This dose is believed to
be below the threshold resulting in toxicity
and so can be used to extrapolate a “safe”
dose for the public, including sensitive sub-
groups. For perchlorate, there is disagreement
over where this NOAEL exists. The critical
study used by the NAS involved 14-day expo-
sure of adult humans in which perchlorate
induced a dose-dependent decline in iodine
uptake into the thyroid (Greer et al. 2002).
The U.S. EPA called the lowest dose in that
study a LOAEL (lowest observable adverse
effect level), whereas the NAS called it a
NOAEL on the basis that, although there was
a slight numerical difference from controls, it
was not statistically significant. We should
mention that the NAS actually used the term
“NOEL” (no observed effect level), leaving
out the “adverse” descriptor.
Examination of Figure 1 (from Greer
et al. 2002) reveals that in fact the low-dose
group did show clear evidence of a perchlo-
rate effect based on data from individual
subjects. Of the seven subjects in the low-
dose group (Figure 1D), three showed no per-
chlorate effect on radioiodine uptake. This is
seen as the essentially flat line from baseline
value through 2 weeks of perchlorate exposure
(exposure day 14; E14) and 2 weeks of per-
chlorate-free recovery (postexposure day 15;
P15). However, four low-dose subjects evi-
denced the characteristic perchlorate effect
observed at the higher doses (Figure 1A–C).
Their baseline values decreased after perchlo-
rate exposure and returned to baseline there-
after. The subjects who were resistant to the
perchlorate effect, as shown in Figure 1D, had
baseline values for radioiodine uptake that
were low (< 15%), whereas the responders all
had values > 15%. This trend can be seen in
the higher dose groups as well (Figures 1B,C),
in which the greatest perchlorate effects are in
those whose baseline uptake is highest.
Baseline uptake may be high in those with
induced levels of iodide transporter in
response to suboptimal iodide intake (Dohan
et al. 2003). How this may affect sensitivity to
perchlorate is unclear, although it is possible
that the ability of the method to detect per-
chlorate-induced inhibition in iodide uptake
may be enhanced when starting at a higher
baseline. Whatever the explanation, the indi-
vidual results of Greer et al. (2002) point to
an effect in four of the seven individuals tested
at the lowest dose, indicating that this dose is
an effect level.
The NAS, however, relied on an average of
the group’s response, and called the low dose a
NOAEL rather than a LOAEL. It is true that
the group mean for the low dose was not sta-
tistically different from the control value, but
this was due to the high degree of variability
(Figure 1D). In fact, one “nonresponder” in
the low-dose group had iodide uptake that was
140% of control. This is an influential data
point that tends to obscure uptake inhibition
in other subjects when data are pooled.
It is important to evaluate variable data sets
to determine whether subgroups can be identi-
ﬁed that may have a different threshold for an
effect than the main group. This is especially
true when evaluating human data because of
the greater intersubject variability that can be
anticipated relative to inbred animals. The
data of Greer et al. (2002) point toward a
more sensitive subgroup, which in this case
represents more than half of the test group
but is not evident in the group mean analysis
due to the variable nature of the response. All
of this points to the fact that the small num-
ber of individuals tested at each of the dose
groups [n = 7 at the low dose (Greer et al.
2002)] and the variability inherent in the data
resulted in weak power to identify statistically
significant effects, even where closer inspec-
tion shows that they were present (U.S. EPA
2002a).
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Human exposure to perchlorate is commonplace because it is a contaminant of drinking water,
certain foods, and breast milk. The U.S. Environmental Protection Agency (EPA) conducted a
perchlorate risk assessment in 2002 that yielded a reference dose (RfD) based on both the animal
and human toxicology data. This assessment has been superceded by a recent National Academy
of Science (NAS) review that derived a perchlorate RfD that is 20-fold greater (less stringent) than
that derived by the U.S. EPA in 2002. The NAS-derived RfD was put on the U.S. EPA’s
Integrated Risk Information System (IRIS) database very quickly and with no further public
review. In this commentary we raise concerns about the NAS approach to RfD development in
three areas of toxicity assessment: the dose that the NAS described as a no observable adverse-
effect level is actually associated with perchlorate-induced effects; consideration of uncertainties
was insufﬁcient; and the NAS considered the inhibition of iodine uptake to be a nonadverse effect.
We conclude that risk assessors should carefully evaluate whether the IRIS RfD is the most appro-
priate value for assessing perchlorate risk. Key words: NAS, neurodevelopmental, perchlorate, RfD,
thyroid hormone. Environ Health Perspect 113:1117–1119 (2005). doi:10.1289/ehp.8254 avail-
able via http://dx.doi.org/ [Online 25 May 2005]The influence of this determination on
the RfD is direct: if the lowest dose is a
LOAEL, then one estimates the NOAEL via
application of an uncertainty factor (typically
3- or 10-fold) or via benchmark dose analysis.
Either of these procedures would result in an
RfD below that derived by the NAS (2005)
and more consistent with that initially drafted
by the U.S. EPA (2002a). 
How Much Uncertainty Is
There in the Perchlorate
Database?
Both the NAS (2005) and the U.S. EPA
(2002a) applied a 10-fold intrahuman uncer-
tainty factor, acknowledging that the critical
study examined a small number of healthy,
iodine-replete adults. Perchlorate effects on
iodine uptake and thyroid hormone status may
be more dramatic in pregnant women who are
already somewhat iodine deﬁcient, a high-risk
scenario that is not uncommon (Azizi et al.
2003; Kibirige et al. 2004). Unlike the U.S.
EPA’s 2002 assessment (U.S. EPA 2002a), the
NAS’s assessment did not apply any other
uncertainty factors. One dissenting member of
the NAS committee thought that an additional
uncertainty factor of 3-fold should be applied
to account for additional issues.
We believe that a database uncertainty
factor of 3- to 10-fold is warranted based
upon key data gaps as follows.
Potential for greater toxicity to newborns
from lactational exposure. Perchlorate is
actively transported into breast milk, where
relatively high levels have been reported in the
United States and Chile (Gibbs 2004; Kirk
et al. 2005). However, there is very little
information on perchlorate effects from lacta-
tional exposure. This is an important data gap
because perchlorate not only concentrates in
breast milk but also inhibits iodide uptake into
this medium (Kirk et al. 2005). Therefore, the
nursing infant may receive less iodide at the
same time that it receives a dose of perchlorate
that may inhibit iodide use.
A rat study by Argus Research Laboratories,
Inc. (2001), which involved a combination of
gestational and lactational exposure, found
postnatal effects on thyroid hormone status at
low doses. However, it is difﬁcult to separate
the effects of lactational and gestational expo-
sure in this study, and all doses were associ-
ated with effects, so a NOAEL was not
established. Regarding human lactational
exposure, there is also very limited informa-
tion. The Chilean study (Crump et al. 2000)
did involve lactational exposure to breast milk
and found no effects on newborn thyroid-
stimulating hormone (TSH) levels in areas
with high levels of perchlorate in drinking
water. However, women in the Chilean high-
perchlorate area did not have lower iodine
content in breast milk relative to the control
area despite relatively high levels of perchlo-
rate in breast milk (Crump et al. 2000; Gibbs
2004). This is in contrast to recent results in
the United States in which there was an
inverse relationship between perchlorate and
iodide levels in breast milk (Kirk et al. 2005).
The difference in breast milk iodide results
may be related to the high intake of iodide in
the Chilean areas studied, considerably higher
than that common in the United States (NAS
2005). The postnatal parameters evaluated in
the Chilean study (Crump et al. 2000) are
also very limited (serum TSH concentrations,
evidence of goiter). The lack of useful lacta-
tional exposure studies is a critical data gap
that adds uncertainty to perchlorate risk
assessment.
Uncertain relationship between short-term
and chronic perchlorate toxicity. The key
study is of 14 days’ duration (Greer et al.
2002). There is uncertainty that longer-term
exposure may have a cumulative effect due to
prolonged perturbation of iodine transport or
increasing storage of perchlorate in the thyroid
and other tissues. A study in rats suggests
greater perchlorate toxicity to the thyroid from
90-day exposure than from 14-day exposure
(Springborn Laboratories 1998). One longer-
term study in humans was reported only as an
abstract (Braverman et al. 2004). Three- or
6-month exposure to perchlorate caused no
effects on thyroid hormone status or iodine
uptake inhibition in small numbers of sub-
jects (n ≤ 5/group). The dose levels should
have been high enough to inhibit iodine
uptake based on the 14-day studies of Greer
et al. (2002). Although this might indicate an
adaptive response to longer-term perchlorate
exposure, this study (Braverman et al. 2004)
lacked statistical analysis and has not been
formally published or peer reviewed, and it is
uncertain whether it had sufficient power to
detect an effect.
What Is an Adverse Effect? 
Part of the NAS rationale for not including any
other uncertainty factors is that they consider
the critical end point, perchlorate-induced
iodine uptake inhibition in the thyroid, as a
precursor effect, but not an adverse effect
(NAS 2005). The NAS states that perchlorate’s
toxic effects on brain development would not
occur unless thyroid hormone levels available to
the fetus or neonate are diminished. Inhibition
of iodine uptake is a step in this pathway, but
compensatory mechanisms may prevent an
effect on circulating thyroid hormone levels.
The NAS stated that one would need a 75%
inhibition in iodine uptake for the perchlorate
effect to be adverse. However, this statement
was not supported with evidence or references,
and it is unclear whether the NAS meant this
to apply to all individuals or just healthy adults
replete in iodine and thyroid hormone.
The issue of what constitutes an adverse
effect has been debated in risk assessment cir-
cles from time to time. Adaptive responses
such as induction of hepatic metabolizing
enzymes in response to agents such as pheno-
barbital are generally considered to be non-
adverse and are not used to formulate an RfD
(Williams and Iatropoulos 2002). However,
precursor effects that are part of the toxic
pathway are of concern. The risk assessment
process acknowledges that other exposures or
disease states may also affect the mode of
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Figure 1. Radioiodine (123I) uptake (RAIU) inhibition proﬁles at various perchlorate doses in human subjects
over 2 weeks of exposure, followed by 2 weeks of recovery. (A) 0.5 mg/kg/day. (B) 0.1 mg/kg/day.
(C) 0.02 mg/kg/day. (D) 0.007 mg/kg/day. BV, baseline value. Reprinted from Greer et al. (2002) with permis-
sion from Environmental Health Perspectives.action of the chemical under consideration or
may contribute to the adverse effect by some
other means. Regarding perchlorate, inhibi-
tion of iodine uptake may be compounded by
factors that exist in at least some pregnant
women and neonates—reduced stores of
iodine and thyroid hormone. Therefore, the
perchlorate precursor effect seen in healthy
adult subjects should be viewed as a critical
effect that warrants prevention.
This strategy is consistent with RfD-setting
policy at the U.S. EPA (2002b), which states
The critical effect is defined as the first adverse
effect, or its known precursor, that occurs to the
most sensitive species, as the dose rate of the agent
increases.
RfDs have been set based on precursor bio-
chemical changes such as plasma or red cell
cholinesterase inhibition for various organo-
phosphates [e.g., chlorpyrifos (U.S. EPA
2004a) and malathion (U.S. EPA 2004b)].
Where the distinction between precursor
and adverse effect may become important
regards how large a LOAEL-to-NOAEL fac-
tor should be used. For mild or precursor
effects, one might choose to use a smaller
LOAEL-to-NOAEL factor than if one were
extrapolating from a clearly toxic effect. For
this reason, the LOAEL-to-NOAEL factor for
perchlorate based upon iodine uptake inhibi-
tion (Greer et al. 2002) may reasonably be set
at 3-fold rather than 10-fold. However, the
distinction between precursor and adverse
effect does not normally affect the size of
other uncertainty factors considered in RfD
determination, such as database deficiencies.
Therefore, we do not see the distinction that
the NAS made between precursor and adverse
effect as affecting the RfD-setting process
except as a consideration in choosing a
LOAEL-to-NOAEL uncertainty factor.
The factors described above lead us to
conclude that the perchlorate RfD derived by
the NAS and now on IRIS (U.S. EPA 2005)
is higher than what is needed to protect pub-
lic health with a reasonable margin of safety.
We recommend that risk assessors carefully
evaluate the IRIS RfD in terms of whether
this RfD is based upon a valid NOAEL and
whether sufficient uncertainty factors have
been applied. The importance of reevaluating
the perchlorate RfD is underscored by the
issues we raise in this commentary, by the
potential for widespread human exposure
in utero and for nursing infants, and because
there has been no opportunity for public
comment on the U.S. EPA’s IRIS value (U.S.
EPA 2005) once the NAS completed its
review (NAS 2005).
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